The WCM CLC Flow Cytometry Core Facility offers state-of-the-art fluorescence activated cell sorting (FACS) instruments and services, and expertise in their applications, to the Weill Cornell Medicine (WCM) community and to outside investigators.
LNC aims to use this license to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders.
Symflor, who previously licensed the Christensenlla patent, has assisted LNC in this transaction. It’s a key step in establishing our leadership position for the Christensenella family and anticipating its future therapeutic applications.” “Securing a license for the Christensenella patent has reinforced our existing intellectual property portfolio. “Expanding our intellectual property is essential in order for us to successfully pursue our vision and our development strategy,” Christensenella and microbiome modulation is an innovative approach with the potential to unlock a wide range of therapeutic applications.īy securing a license for the Christensenella patent, LNC has bolstered its strategy for developing innovative therapeutic approaches based on this new family of bacteria. Considered a keystone taxon in the human gut microbiome, it represents a major opportunity in the fight against obesity, metabolic disorders and other high-impact diseases. LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery announced that it has signed an exclusive license agreement with Cornell University (Ithaca, NY, USA ) for its Christensenella patent family.Ĭhristensenella is a recently discovered family of gut bacteria.